In the first study (Study 1), we evaluated whether FXS-like neurobehavioral phenotypes could be rescued by a sub-chronic (10-day) CBDV treatment that started at adulthood, i.e., once the pathology is fully expressed in the Fmr1-KO mouse model [36]. This evidence concerns the gene FMR1 and fragile X syndrome.